Skip to main content
. 2021 Sep 28;16:399. doi: 10.1186/s13023-021-02021-x

Fig. 1.

Fig. 1

Recruitment details of the HAEKA study as per 07.10.2020. a Number of participants enrolled per study site. b A boxplot displaying the age distribution of the participants. c Gender distribution of the participants. d Visit status of all participants in the HAEKA study. The number of completed Visits 1–7 is shown. e Prophylactic treatment of HAEKA participants: it is shown how many participants take each respective medication (one subject received both Lanadelumab and Berinert®). f An overview showing how often the different samples af of each attack have been collected. g Acute treatment of HAE attacks: it is shown how many percent of the participants take a respective medication to treat an attack. h Overview on the amount of documented attacks per participant. i Exemplary CentoCard® showing the quality of participant’s self-sampled blood spots